BDX

Prezzo Becton Dickinson & Co

Closed
BDX
$149,31
+$0,27(+0,18%)

*Data last updated: 2026-05-04 07:21 (UTC+8)

As of 2026-05-04 07:21, Becton Dickinson & Co (BDX) is priced at $149,31, with a total market cap of $54,09B, a P/E ratio of 19,75, and a dividend yield of 2,50%. Today, the stock price fluctuated between $146,42 and $154,22. The current price is 1,97% above the day's low and 3,18% below the day's high, with a trading volume of 1,81M. Over the past 52 weeks, BDX has traded between $143,30 to $158,64, and the current price is -5,88% away from the 52-week high.

BDX Key Stats

Yesterday's Close$149,04
Market Cap$54,09B
Volume1,81M
P/E Ratio19,75
Dividend Yield (TTM)2,50%
Dividend Amount$1,05
Diluted EPS (TTM)6,16
Net Income (FY)$1,67B
Revenue (FY)$21,83B
Earnings Date2026-05-07
EPS Estimate2,77
Revenue Estimate$4,66B
Shares Outstanding362,95M
Beta (1Y)0.352
Ex-Dividend Date2026-06-09
Dividend Payment Date2026-06-30

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
SectorHealthcare
IndustryMedical - Instruments & Supplies
CEOThomas E. Polen Jr.
HeadquartersFranklin Lakes,NJ,US
Official Websitehttps://www.bd.com
Employees (FY)72,00K
Average Revenue (1Y)$303,31K
Net Income per Employee$23,30K

Becton Dickinson & Co (BDX) FAQ

What's the stock price of Becton Dickinson & Co (BDX) today?

x
Becton Dickinson & Co (BDX) is currently trading at $149,31, with a 24h change of +0,18%. The 52-week trading range is $143,30–$158,64.

What are the 52-week high and low prices for Becton Dickinson & Co (BDX)?

x

What is the price-to-earnings (P/E) ratio of Becton Dickinson & Co (BDX)? What does it indicate?

x

What is the market cap of Becton Dickinson & Co (BDX)?

x

What is the most recent quarterly earnings per share (EPS) for Becton Dickinson & Co (BDX)?

x

Should you buy or sell Becton Dickinson & Co (BDX) now?

x

What factors can affect the stock price of Becton Dickinson & Co (BDX)?

x

How to buy Becton Dickinson & Co (BDX) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Becton Dickinson & Co (BDX)

FUD_Whisperer

FUD_Whisperer

04-30 17:48
Just caught something interesting in the medical device space that might be worth paying attention to. BD got CE Mark approval for their Revello Vascular Covered Stent, and honestly, this could be a bigger deal than the flat stock reaction suggests. Here's what's happening: the stent is specifically designed for treating atherosclerotic lesions in the common iliac and external iliac arteries. It's a next-gen endovascular device that combines a self-expanding nitinol stent with an ultrathin expanded PTFE covering. The engineering here is pretty solid—tantalum markers for better visibility, compliant stent ends to minimize trauma, and a tri-axial delivery system that gives physicians real control during deployment. They've got it in multiple diameters and catheter lengths too, which means better flexibility in actual procedures. What caught my eye is the market timing. The global peripheral artery disease treatment market was valued at around $3.17 billion in 2025 and is projected to hit $6.11 billion by 2034—that's a 7.56% CAGR. Europe's aging population means PAD is becoming increasingly common, and minimally invasive solutions like the Revello are exactly what hospitals are looking for. BD's already got the device being tested in the AGILITY clinical trial, and they introduced it at LINC 2026 in Germany. The stock is down 11.3% over the past six months while the industry grew 17.2%, so there's definitely been some pressure on BDX. But long-term, this kind of portfolio expansion in peripheral vascular intervention could be the steady growth driver the market's been missing. If BD can capture incremental procedure volumes in common iliac artery treatments and build deeper relationships with hospitals and physicians, that's recurring revenue from minimally invasive procedures—exactly the kind of secular trend that holds up. BD also just got FDA clearance for the Surgiphor antimicrobial irrigation system and launched the BD Research Cloud 7.0 with AI-driven tools for flow cytometry. They're clearly pushing innovation across multiple segments. Worth monitoring if you're looking at medical device exposure with some European upside potential.
0
0
0
0
TheMemefather

TheMemefather

04-30 17:38
Just caught something interesting about BD's latest move in the vascular space. They've gotten CE Mark approval for their Revello Vascular Covered Stent in Europe, which is basically them doubling down on peripheral artery disease treatment as the market grows. The stent itself is pretty thoughtfully engineered - self-expanding nitinol with an ultrathin covering, tantalum markers for better visibility, all designed to adapt to natural vessel anatomy without causing trauma to healthy tissue. What's notable here is the timing. Europe's aging population means PAD is becoming increasingly common, and BD is positioning itself to capture more procedure volume in iliac artery treatments. The company's market cap sits around $48.8 billion, and with this approval, they're essentially expanding their peripheral vascular intervention footprint at a moment when the market is accelerating. Industry forecasts suggest the global PAD treatment market could grow from $3.17 billion in 2025 to $6.11 billion by 2034 - that's a 7.56% CAGR, so there's real growth here. What caught my attention though is how BD is simultaneously strengthening its broader portfolio beyond just stents. They recently launched BD Research Cloud 7.0, which includes their new flow cytometry panel tool - the BD Horizon Panel Maker. This AI-driven system automates flow cytometry panel design for immunology and oncology research, which is a different but complementary angle to their device strategy. It shows they're not just chasing procedure volumes but also building out their life sciences research capabilities. The Revello stent itself comes with a tri-axial delivery system featuring an atraumatic tip and a thumbwheel mechanism for precise placement - the kind of thoughtful design you see when companies are serious about minimally invasive solutions. BD introduced it at LINC 2026 in Germany and it's currently in the AGILITY clinical trial. Stock-wise, BDX has been relatively flat since the announcement, down about 11.3% over the past six months while the broader industry gained 17.2%. But if you're looking at the longer-term picture, this CE Mark approval combined with their expanding vascular portfolio and innovation in areas like flow cytometry panel automation suggests BD is building a more comprehensive ecosystem for both interventional procedures and research workflows. That kind of portfolio depth typically supports sustained growth in the medical device space, especially as hospitals and physicians increasingly value integrated solutions.
0
0
0
0